Medullary Carcinoma of Thyroid explained & Management essay with diagrams & flowcharts under 1000 words

Reading File

Finding Sources

Searching Images

medullary carcinoma thyroid histology amyloid

Reading File

Loading Image

Now I have everything needed. Here is the comprehensive essay:

Medullary Carcinoma of the Thyroid (MTC)

1. Definition & Cell of Origin

Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy arising from the parafollicular C cells of the thyroid — not from follicular cells. C cells produce calcitonin, and this hormonal signature is the cornerstone of both diagnosis and follow-up. MTC accounts for approximately 5–10% of all thyroid cancers but carries a disproportionate prognostic burden. — Robbins & Kumar Basic Pathology

2. Classification: Sporadic vs. Familial

┌────────────────────────────────────────────────────────┐
│             MEDULLARY THYROID CARCINOMA                │
│                                                        │
│  ┌─────────────────────┐   ┌──────────────────────┐   │
│  │   SPORADIC (~70%)   │   │   FAMILIAL (~30%)    │   │
│  │  • Adults, 5th–6th  │   │  • Germline RET      │   │
│  │    decade           │   │    mutation           │   │
│  │  • Usually solitary │   │  • Bilateral &       │   │
│  │  • Somatic RET mut. │   │    multicentric       │   │
│  └─────────────────────┘   └──────────┬───────────┘   │
│                                        │               │
│               ┌────────────────────────┤               │
│               ▼            ▼           ▼               │
│          MEN 2A          MEN 2B    Familial MTC        │
│    (MTC+Pheo+HPT)   (MTC+Pheo+   (MTC alone,          │
│                      Marfanoid +  no MEN features)     │
│                      Neuromas)                         │
└────────────────────────────────────────────────────────┘

MEN 2A (Sipple syndrome): MTC + pheochromocytoma (~50%) + hyperparathyroidism (20–30%)
MEN 2B: MTC + pheochromocytoma + marfanoid habitus + mucosal neuromas — most aggressive form; tumors arise earlier and grow faster
Familial MTC without MEN: intermediate aggressiveness
In familial forms, MTC is usually the first tumor to develop, typically in the second or third decade of life — Mulholland & Greenfield's Surgery

3. Molecular Pathogenesis

The RET proto-oncogene (chromosome 10q11.2) is central to MTC:

  RET proto-oncogene mutation
          │
     Gain-of-function
          │
   Constitutive RET kinase
   activation (tyrosine
   kinase receptor)
          │
   ┌──────┴──────┐
   │             │
Germline      Somatic
(Familial)   (Sporadic ~50%)
   │
   ▼
C-cell hyperplasia → Micromedullary CA → Invasive MTC
(precursor lesion)

All patients with MTC must be tested for RET mutations to enable genetic counselling and prophylactic management of family members. — Harrison's Principles of Internal Medicine 22E

4. Pathology

Gross: Solid, firm, tan-brown to grey mass, often without a capsule; larger tumours show haemorrhage and necrosis with possible capsular extension.

Microscopy: Polygonal to spindle-shaped cells arranged in nests, trabeculae, or gland-like structures. The hallmark is amyloid deposition in the stroma — derived from altered calcitonin molecules — identifiable as homogeneous pink extracellular material on H&E, and Congo red positive with apple-green birefringence under polarised light.

MTC gross and microscopic pathology — (A) bisected solid mass without fibrous capsule; (B) abundant homogeneous pink stromal amyloid

Fig. 1 — MTC gross specimen (A) and H&E histology with stromal amyloid (B). — Robbins & Kumar Basic Pathology

H&E high-power view showing MTC C-cells with granular cytoplasm, salt-and-pepper nuclei, and surrounding pink amyloid with foreign-body giant cell reaction

Fig. 2 — High-power H&E: nests of C-cells with granular cytoplasm, amyloid deposits, and foreign-body giant cell reaction.

Immunohistochemistry: Positive for calcitonin, CEA, chromogranin A, synaptophysin, TTF-1; negative for thyroglobulin (distinguishing MTC from follicular-derived carcinomas).

Familial hallmark: C-cell hyperplasia in surrounding parenchyma — the precursor lesion — virtually absent in sporadic MTC.

5. Clinical Features

Feature	Detail
Presentation	Neck mass; hoarseness/dysphagia if compressing
Diarrhoea	Secretory; due to VIP/calcitonin (severe in advanced disease)
Cervical nodes	Palpable in many at presentation
Ectopic hormones	ACTH (Cushing's), serotonin, prostaglandins

Basal plasma calcitonin is markedly elevated. After calcium/pentagastrin stimulation, levels rise >1,000 pg/mL (normal stimulated peak <200 pg/mL) — a sensitive test for occult or recurrent disease. — Mulholland & Greenfield's Surgery

6. Diagnosis & Workup

Suspected Thyroid Nodule / ↑ Calcitonin / Family History of MTC
                        │
              ┌─────────▼──────────┐
              │ Serum Calcitonin   │
              │ & CEA levels       │
              └─────────┬──────────┘
                        │ Elevated
              ┌─────────▼──────────┐
              │  FNA Cytology       │  ← spindle/polygonal cells,
              │  + IHC (calcitonin) │     amyloid
              └─────────┬──────────┘
                        │
              ┌─────────▼──────────┐
              │   RET Mutation      │
              │   Testing (germline)│
              └─────────┬──────────┘
                        │
         ┌──────────────┴───────────────┐
         ▼                              ▼
    RET Positive                   RET Negative
    → Screen family                → Sporadic MTC
    → Screen for Pheo              → Local staging
    → Screen for HPT               
         │
    ┌────▼────────────────────────────────┐
    │ If RET+ → EXCLUDE PHEO FIRST        │
    │ (urine/plasma metanephrines, CT/MRI)│
    └─────────────────────────────────────┘
                        │
              ┌─────────▼──────────┐
              │ Staging:            │
              │ Neck U/S, CT Chest  │
              │ Abdomen, FDG-PET    │
              │ (hepatic/skeletal   │
              │  metastasis)        │
              └────────────────────┘

7. Management

Surgery — the only curative modality

┌──────────────────────────────────────────────────────────────┐
│                    SURGICAL MANAGEMENT                       │
├──────────────────────────────────────────────────────────────┤
│                                                              │
│  CLINICALLY EVIDENT MTC:                                     │
│  Total thyroidectomy +                                       │
│  Bilateral central neck dissection                           │
│  + Ipsilateral lateral neck dissection                       │
│    (if tumour >1 cm or central node metastasis)              │
│                                                              │
│  PROPHYLACTIC (RET mutation, no clinical MTC):               │
│  Total thyroidectomy + central neck dissection               │
│  Timing by RET mutation risk category:                       │
│    Highest risk (MEN 2B, C634F/Y) → age <1 year             │
│    High risk → age <5 years                                  │
│    Moderate risk → age 5–10 years                            │
│                                                              │
│  Post-op: lifelong levothyroxine replacement                 │
│  ~90% of young prophylactic patients: no recurrence at 7 yrs │
└──────────────────────────────────────────────────────────────┘

Important: Pheochromocytoma must be excluded before surgery in all RET-mutation carriers, as undetected phaeochromocytoma causes intraoperative hypertensive crises. — Harrison's Principles of Internal Medicine 22E

Postoperative Monitoring

Serum calcitonin and CEA at 3 months post-op and then periodically
Rising calcitonin → provocative testing → re-operative neck dissection (including mediastinal exploration) can normalise calcitonin and achieve biochemical cure

Advanced / Metastatic Disease

Unlike differentiated thyroid cancer, MTC does not take up radioiodine — ¹³¹I has no role.

Treatment	Role
Vandetanib / Cabozantinib (TKIs)	First-line for unresectable/metastatic MTC; improve progression-free survival
Selpercatinib	Selective RET kinase inhibitor; most effective agent; preferred for RET-mutated MTC
¹⁷⁷Lu-DOTATATE (PRRT)	For somatostatin receptor-positive MTC on SRS
External beam radiotherapy	Palliative; local disease control
Chemotherapy	Limited efficacy; not standard

— Harrison's Principles of Internal Medicine 22E

8. Prognosis

10-year survival in metastatic MTC: ~20%
MEN 2A: often indolent; survival prolonged even with metastases
MEN 2B: aggressive; early death possible
Familial MTC (non-MEN): intermediate
Biochemical cure (normalised calcitonin) = best surrogate for survival

Summary Flowchart

MTC DIAGNOSIS
     │
     ├─ Sporadic (70%) ──→ Total thyroidectomy + central dissection
     │                      → Monitor calcitonin/CEA post-op
     │
     └─ Familial (30%) ──→ Germline RET testing
          │
          ├─ MEN 2A / 2B ──→ Exclude Pheo first
          │                   → Total thyroidectomy (timing by risk)
          │                   → Screen for HPT (MEN 2A)
          │
          └─ Recurrent/Metastatic ──→ Selpercatinib (RET+)
                                       Vandetanib / Cabozantinib
                                       PRRT if SSTR+
                                       Radiotherapy (palliation)

Sources: Robbins & Kumar Basic Pathology; Harrison's Principles of Internal Medicine 22E; Mulholland & Greenfield's Surgery 7e; Robbins, Cotran & Kumar Pathologic Basis of Disease

Iatrogenic Facial Nerve Palsy - essay for ENT exam under 1000 words with flowcharts & diagrams.

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Searching Images

facial nerve anatomy parotid branches surgical

Loading Image

Reading File

I now have comprehensive textbook content. Let me compile the essay.

Iatrogenic Facial Nerve Palsy

An ENT Exam Essay

1. Introduction

Iatrogenic facial nerve palsy is one of the most feared complications in head and neck surgery. The facial nerve (CN VII) has a long, tortuous course through the temporal bone and parotid gland, rendering it vulnerable at multiple points during surgical procedures. Consequences range from temporary weakness to permanent paralysis, with profound functional (eye closure, oral competence) and psychological impact on the patient. — Cummings Otolaryngology

2. Anatomy at Risk

Intraoperative dissection of the extratemporal facial nerve after parotidectomy, showing all five terminal branches: temporal, zygomatic, buccal, marginal mandibular, and cervical

Intraoperative dissection of the extratemporal facial nerve showing all five terminal branches — a critical visual for understanding surgical anatomy.

COURSE OF THE FACIAL NERVE — SITES OF SURGICAL VULNERABILITY
═══════════════════════════════════════════════════════════════

  Brainstem (pons)
       │
  Internal Auditory Canal (IAC) ←─── Acoustic neuroma surgery
       │
  Labyrinthine segment
  (geniculate ganglion) ←──────────── Temporal bone fracture /
       │                              middle fossa approach
  Tympanic (horizontal) segment ←─── Cholesteatoma / tympanoplasty /
       │                              ossiculoplasty
  Mastoid (vertical) segment ←─────── Mastoidectomy (most common
       │                               iatrogenic site)
  Stylomastoid foramen
       │
  Extratemporal (parotid) ←────────── Parotidectomy / parotid surgery
       │
  ┌────┴────────────────────────────┐
  Temporal | Zygomatic | Buccal |
  Marginal Mandibular | Cervical ←── Facelift, neck dissection,
                                      submandibular gland excision

The mastoid (vertical) segment is the most commonly injured intratemporal site; the marginal mandibular branch is the most commonly injured extratemporal branch. — Schwartz's Principles of Surgery

3. Causes & Operations at Risk

Operation	Mechanism of Injury
Mastoidectomy	Direct trauma to vertical segment; most common cause overall
Parotidectomy	Traction, thermal, or transection injury to main trunk / branches
Acoustic neuroma / CPA surgery	Stretch/traction on nerve at IAC or brainstem
Middle ear / tympanoplasty	Exposed or dehiscent tympanic segment
Stapedectomy	Abnormal nerve overhanging oval window
Neck dissection	Marginal mandibular branch at submandibular triangle
Parotid / submandibular excision	Peripheral branch injury
Facelift (rhytidectomy)	Temporal or zygomatic branches
Temporal bone fracture surgery	Compression, haematoma, entrapment at labyrinthine segment / geniculate ganglion

4. Mechanisms of Nerve Injury (Sunderland Classification)

┌──────────────────────────────────────────────────────────────┐
│          MECHANISMS OF IATROGENIC NERVE INJURY               │
├────────────────┬─────────────────────────────────────────────┤
│ Neuropraxia    │ Conduction block only; axon intact           │
│ (Grade I)      │ → Full spontaneous recovery expected         │
├────────────────┼─────────────────────────────────────────────┤
│ Axonotmesis    │ Axon disrupted; endoneurium intact           │
│ (Grade II-IV)  │ → Partial/full recovery with time            │
├────────────────┼─────────────────────────────────────────────┤
│ Neurotmesis    │ Complete transection                         │
│ (Grade V)      │ → No spontaneous recovery; repair required   │
└────────────────┴─────────────────────────────────────────────┘

Intraoperative causes:
  • Traction / stretching
  • Thermal (diathermy, drill heat)
  • Compression (packing, retractors)
  • Transection / laceration
  • Devascularisation
  • Oedema / haematoma (delayed onset)

5. Recognition & Intraoperative Management

INTRAOPERATIVE FACIAL NERVE CONCERN
             │
    ┌────────▼─────────┐
    │ Positively ID     │
    │ nerve using       │
    │ distant landmarks │
    └────────┬──────────┘
             │
    ┌────────▼──────────────────────────────────┐
    │ Trace nerve to site of suspected injury   │
    └────────┬──────────────────────────────────┘
             │
    ┌────────▼─────────────────────────────────────────┐
    │ Assess extent of injury                          │
    │  < 50% diameter → local decompression, observe   │
    │  > 50% diameter → primary reanastomosis          │
    │  Gap / loss of tissue → interposition nerve graft │
    │        (great auricular or sural nerve)           │
    └────────┬─────────────────────────────────────────┘
             │
    If landmarks NOT discernible:
    STOP dissection. Seek senior / specialist consultation.

Intraoperative adjuncts:

Facial nerve integrity monitor (FNIM / EMG): Provides real-time feedback via auditory alarm on nerve stimulation; mandatory in acoustic neuroma, parotid, and revision ear surgery
Nerve stimulator probe: Localises the nerve in difficult fields

6. Postoperative Management Flowchart

POST-OP FACIAL WEAKNESS NOTED
             │
    ┌────────▼──────────────────────────────┐
    │ Is this EXPECTED (warned) or SURPRISE? │
    └────────┬──────────────────────────────┘
             │
     ┌───────┴──────────┐
     ▼                  ▼
  Expected            Surprise (unexpected)
  (e.g. planned       ─────────────────────
  nerve sacrifice)    1. Release tight dressings & packing
     │                2. Allow local anaesthetic to dissipate
     ▼                   (wait 30–60 min)
  Conservative        3. If no recovery → URGENT re-exploration
  management             and decompression
  + rehab             4. Identify & address site of injury
                      5. Intraop repair if needed

SEVERITY ASSESSMENT (House-Brackmann Grade)
  I   — Normal
  II  — Mild dysfunction; complete eye closure with effort
  III — Moderate; obvious asymmetry; complete eye closure
  IV  — Moderately severe; incomplete eye closure
  V   — Severe; barely perceptible movement
  VI  — Total paralysis

Electrophysiological testing (ENoG / EMG):

ENoG showing >90% degeneration within 6 days → consider surgical decompression
EMG: detects fibrillation potentials (denervation) vs. polyphasic units (reinnervation)
Long-standing paralysis: if no clinical or EMG recovery at 12 months → surgical exploration indicated — Cummings Otolaryngology

7. Treatment of Established Palsy

Timing	Intervention
Immediate (intraop)	Primary neurorrhaphy / interposition nerve graft
Early (<3 weeks)	Re-explore; nerve graft if needed
Intermediate (weeks–months)	Eye care (lubricants, taping, moisture chamber); physiotherapy; gold weight upper eyelid implant for lagophthalmos
Late / permanent	Facial reanimation: hypoglossal-facial anastomosis; microneurovascular free muscle transfer (temporalis/latissimus dorsi); static slings; brow lift

Eye care is paramount — incomplete lid closure causes corneal exposure, dryness, and potential blindness.

8. Prevention

KEY PREVENTIVE PRINCIPLES
─────────────────────────
✓ Thorough anatomical knowledge of the facial nerve course
✓ Pre-op imaging (MRI/CT) to identify aberrant anatomy
✓ Routine intraoperative nerve monitoring
✓ Meticulous surgical technique; avoid excessive traction
✓ Minimal use of monopolar diathermy near nerve
✓ Adequate decompression; avoid tight postoperative packing
✓ Informed consent — discuss risk explicitly before surgery
✓ Identify high-risk patients (revision surgery, parotid tumours,
  cholesteatoma, temporal bone fractures)

9. Summary

Iatrogenic facial nerve palsy results from surgical injury during mastoidectomy, parotidectomy, CPA surgery, or neck dissection. The vertical segment of the mastoid is the most common intratemporal site; the marginal mandibular branch is most vulnerable extracranially. Intraoperative recognition demands immediate assessment and repair; unexpected postoperative palsy requires urgent re-exploration. Outcomes depend on extent of injury — neuropraxia recovers fully, while neurotmesis requires surgical reconstruction. Prevention through nerve monitoring, anatomical expertise, and careful dissection remains the gold standard.

Sources: Cummings Otolaryngology Head and Neck Surgery; Schwartz's Principles of Surgery 11e; Localization in Clinical Neurology 8e

This is a shared conversation. Sign in to Orris to start your own chat.